À retenir
Pooling 4 studies (1,079 participants), acute hyperglycemic phenotypes were associated with higher short-term all-cause mortality (RR 2.09, 95% CI 1.21-3.64), and pooling 3 studies (679 participants) with invasive mechanical ventilation (RR 3.64, 95% CI 1.74-7.61). The estimates were unadjusted and based on few studies with differing definitions, so they should not be read as causal.
Study design
Revue des preuves
Reading basis
Published abstract
Reading focus
Design & applicability
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
COVID-19 can disturb blood sugar control through inflammation, fat tissue dysfunction and impaired insulin signaling. The authors gathered the scattered evidence to ask how glucose and insulin resistance behave in acute and post-acute COVID-19, and whether high blood sugar predicts worse outcomes.
Population et méthode
Systematic review and meta-analysis searching PubMed, Embase, Scopus, Web of Science and ScienceDirect. Studies had to measure glucose regulation and at least one insulin-resistance or insulin-sensitivity measure during or after COVID-19. Prognostic evidence was pooled as unadjusted risk ratios from event counts, using restricted maximum-likelihood random-effects models with Hartung-Knapp adjustment, while evidence that could not be combined was summarized following Synthesis Without Meta-analysis principles. Risk of bias was assessed with design-appropriate tools and certainty with GRADE. The protocol was registered retrospectively in OSF.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 120 independent studies (23 reports) were included.
- 2Acute hyperglycemic phenotypes were associated with higher short-term all-cause mortality (4 studies; 1,079 participants; RR 2.09, 95% CI 1.21-3.64; I^2 = 31.3%). The 95% prediction interval, 0.96-4.56, includes no effect, so the effect in a new setting is uncertain.
- 3They were also associated with invasive mechanical ventilation (3 studies; 679 participants; RR 3.64, 95% CI 1.74-7.61; I^2 = 0%). Adding a large study that used peak in-hospital glucose kept the mortality association but produced substantial heterogeneity for ventilation.
- 4After COVID-19 there was no single pattern: insulin resistance or glucose abnormalities resolved in some groups, persisted in others, and progressed to newly diagnosed diabetes in a subset.
Limites et incertitude
- 1The pooled risk ratios are unadjusted, so differences in age, severity or other illness may explain them; the authors state they are not causal.
- 2The mortality prediction interval (0.96-4.56) includes 1, and the pooled analyses combine only 3 to 4 studies each.
- 3The hyperglycemic phenotypes were defined differently by each study, and insulin-resistance assessment was only an eligibility criterion, not part of a combined exposure.
- 4The protocol was registered retrospectively, and post-COVID trajectories could be summarized only narratively; this reading is based on the abstract only.
Mise en perspective
High blood sugar during a COVID-19 hospital stay marked patients at higher risk, but this does not show that lowering glucose would change outcomes. Longer-term, some people had lasting glucose problems after infection, so those with new symptoms of high blood sugar should raise them with a clinician.
Vos données
If you have diabetes or prediabetes, glucose meter or CGM trends and HbA1c are the relevant personal data, and a spell of illness may temporarily push readings up. Compare with your own baseline on the same device and share notable shifts with your clinician rather than interpreting them alone.
Comprendre ce type de preuve
Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Background
Coronavirus disease 2019 (COVID-19) can disrupt glucose regulation through inflammation, adipose-tissue dysfunction, impaired insulin signaling, and variable β-cell compensation. These evidence domains remain incompletely integrated.
Objective
To synthesize evidence on glycemic dysregulation and insulin resistance or insulin sensitivity across acute and post-acute COVID-19, including metabolic trajectories and associations with adverse clinical outcomes.
Methods
PubMed, Embase, Scopus, Web of Science, and ScienceDirect were searched. Eligible studies evaluated glucose regulation and at least one insulin-resistance or insulin-sensitivity measure during or after COVID-19. Etiological and prognostic evidence was analyzed as related but distinct domains. Prognostic meta-analysis evaluated study-defined acute hyperglycemic phenotypes; insulin-resistance or insulin-sensitivity assessment was a study-level eligibility criterion rather than part of a participant-level composite exposure. Unadjusted risk ratios (RRs) from event counts were pooled using restricted maximum-likelihood random-effects models with Hartung-Knapp adjustment. Non-combinable evidence was synthesized according to Synthesis Without Meta-analysis principles. Risk of bias was assessed using design-appropriate tools, and certainty was evaluated with GRADE. The protocol and analytical plan were retrospectively registered in OSF on August 21, 2026 (https://doi.org/10.17605/OSF.IO/K5FWU).
Results
Twenty independent studies represented by 23 reports. Acute hyperglycemic phenotypes were associated with increased short-term all-cause mortality (four studies; 1,079 participants; RR 2.09, 95% confidence interval [CI] 1.21-3.64; I^(2)=31.3%; 95% prediction interval 0.96-4.56) and invasive mechanical ventilation (three studies; 679 participants; RR 3.64, 95% CI 1.74-7.61; I^(2)=0%). Mortality estimates remained directionally stable in sensitivity analysis. Adding a large study using peak in-hospital glucose preserved the mortality association but produced substantial heterogeneity for ventilation. Etiological evidence showed no uniform post-COVID trajectory: insulin resistance or glycemic abnormalities resolved in some populations, persisted in others, and progressed toward newly diagnosed diabetes in a subset. Mechanistic evidence implicated inflammatory stress, adipose-tissue dysfunction, impaired insulin signaling, and variable β-cell responses.
Conclusions
Study-defined acute hyperglycemic phenotypes were associated with adverse COVID-19 outcomes in studies that also assessed insulin resistance or insulin sensitivity. These unadjusted estimates should not be interpreted as effects of a combined phenotype or as causal associations. Persistent metabolic abnormalities occurred heterogeneously, supporting standardized participant-level definitions and controlled longitudinal studies.
Systematic review registration
https://doi.org/10.17605/OSF.IO/K5FWU, identifier 10.17605/OSF.IO/K5FWU.
Sources et attribution
Glycemic dysregulation and insulin resistance across acute and post-acute COVID-19: a systematic review and meta-analysis of etiologic and prognostic evidence.
Muñoz-Carrillo JL, Gutiérrez-Coronado O, Lopez-Hernandez E, Rodríguez López SE, Olivares Mendoza MA, Ramírez Águila DO, Villalobos-Gutiérrez PT, Soria-Fregozo C, Rosas-Sánchez GU, Soriano-Hernández AD.
Frontiers in endocrinology · 2026-10-14
DOI: 10.3389/fendo.2026.1975728 ↗PubMed · 42952500 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

